OBI Pharma, Inc. AI Stock Analysis
OBI Pharma, Inc. (4174) AI Stock Analysis
OBI Pharma, Inc.
(TPEx:4174)
The score is held down primarily by very weak fundamentals: negligible and declining revenue, negative gross profit, an annual net loss of about NT$2.05 billion, and widening cash burn that halved shareholders' equity to NT$1.89 billion, creating meaningful near-term financing and dilution risk. Valuation offers no support, with negative earnings and no dividend. The main offset is strong technical momentum — the stock trades well above its 50-, 100- and 200-day moving averages with a positive MACD and neutral RSI — which lifts the score toward the middle of the range, though short-term indicators suggest consolidation after a sharp rally. Overall, this is a speculative, catalyst-driven name whose investment case depends on clinical progress, partnerships or new funding rather than current financial performance.
OBI Pharma, Inc. (4174) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 8.58B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.11M
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 0.22
- Revenue Growth
- -2.20%
- EPS Growth
- 29.08%
- Country
- TW
- Employees
- 260
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
OBI Pharma, Inc. Business Overview & Revenue Model
Company Description
OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's...
OBI Pharma, Inc. Financial Statement Overview
Summary
Financials are extremely weak, consistent with a clinical-stage biotech with no commercial engine. Revenue of roughly NT$58.6 million fell ~7% year over year, gross profit remained negative (-NT$77.5 million) for a fifth straight year, and the net loss was about NT$2.05 billion. Operating cash flow of -NT$2.02 billion and free cash flow of -NT$2.07 billion widened again, halving shareholders' equity to NT$1.89 billion and cutting total assets nearly 40%. Modest offsets include low borrowings (~NT$516 million), minimal capex, and losses that narrowed ~11% versus 2024 — but with the equity cushion covering under a year of burn, funding and dilution risk dominates.
Income Statement
9Very NegativeBalance Sheet
33NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.20M | 58.58M | 62.68M | 41.55M | 4.71M | 18.77M |
| Gross Profit | -135.14M | -77.53M | -76.27M | -73.50M | -40.14M | -25.59M |
| EBITDA | -1.38B | -1.94B | -2.26B | -1.02B | -1.67B | -1.52B |
| Net Income | -1.53B | -2.05B | -2.31B | -1.05B | -1.90B | -1.72B |
Balance Sheet | ||||||
| Total Assets | 2.69B | 3.42B | 5.65B | 5.60B | 6.63B | 4.49B |
| Cash, Cash Equivalents and Short-Term Investments | 496.96M | 1.19B | 3.13B | 2.78B | 4.77B | 2.65B |
| Total Debt | 446.14M | 515.68M | 505.17M | 501.05M | 247.09M | 293.03M |
| Total Liabilities | 495.56M | 696.13M | 833.38M | 650.45M | 497.57M | 615.95M |
| Stockholders Equity | 1.49B | 1.89B | 3.81B | 3.81B | 4.63B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | -1.55B | -2.07B | -1.95B | -1.76B | -1.92B | -1.31B |
| Operating Cash Flow | -1.53B | -2.02B | -1.83B | -1.65B | -1.62B | -1.06B |
| Investing Cash Flow | 629.78M | 908.93M | 483.02M | -2.80B | -169.89M | 82.68M |
| Financing Cash Flow | 69.63M | 141.63M | 2.17B | 607.07M | 4.01B | 163.75M |
OBI Pharma, Inc. Peers Comparison
Overall Rating
TW:173464Neutral
TW:415752Neutral- TW:417448Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:1734 | 64Neutral | TWD 6.07B | 17.33 | ― | 3.13% | 2.44% | -3.96% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4157 | 52Neutral | TWD 5.78B | 37.38 | ― | ― | 530.40% | ― |
| TW:4174 | 48Neutral | TWD 7.23B | -2.37 | ― | ― | -2.20% | 29.08% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4174 | OBI Pharma, Inc. | 60.50 | 11.70 | 23.98% | |
| TW:1734 | Sinphar Pharmaceutical Co. Ltd. | 30.15 | 1.76 | 6.19% | |
| TW:4157 | TaiGen Biopharmaceuticals Holdings Limited | 8.29 | -1.23 | -12.92% | |
| TW:6976 | Acepodia, Inc. | 12.00 | -3.30 | -21.57% | |
| TW:7754 | Annji Pharmaceutical Co., Ltd. | 69.40 | 24.75 | 55.45% | |
| TW:7876 | Obigen Pharma, Inc. | 66.20 | 29.51 | 80.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026